Insmed, Inc. (INSM)

Price$94.22

Value ScoreF

Growth ScoreA

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-62.58%

Price vs S&P 500 (4W)-7.03%

VGM Score44.69

Market Capitalization$20.42B

All Metrics

Book Value / Share (Quarterly)$3.26

P/TBV (Annual)57.88x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)35.20%

Cash Flow / Share (Quarterly)$-4.26

Price vs S&P 500 (YTD)-54.02%

Gross Margin (TTM)81.81%

Net Profit Margin (TTM)-144.44%

EPS (TTM)$-5.74

10-Day Avg Trading Volume3.31M

EPS Excl Extra (TTM)$-5.74

Revenue Growth (5Y)29.83%

EPS (Annual)$-6.42

ROI (Annual)-87.04%

Gross Margin (Annual)79.73%

Net Profit Margin (5Y Avg)-226.84%

Cash / Share (Quarterly)$5.65

Revenue Growth QoQ (YoY)229.62%

ROA (Last FY)-56.38%

Revenue Growth TTM (YoY)115.09%

EBITD / Share (TTM)$-5.52

ROE (5Y Avg)-250.53%

Operating Margin (TTM)-140.56%

Cash Flow / Share (Annual)$-4.52

P/B Ratio28.97x

P/B Ratio (Quarterly)50.08x

Net Income / Employee (Annual)$-767,300

EV / Revenue (TTM)25.10x

Net Interest Coverage (TTM)-53.96x

ROA (TTM)-51.57%

EV / EBITDA (TTM)193.89x

EPS Incl Extra (Annual)$-6.42

Current Ratio (Annual)3.83x

Quick Ratio (Quarterly)3.88x

3-Month Avg Trading Volume2.81M

52-Week Price Return29.53%

Revenue / Employee (TTM)$492,500

Tangible BV / Share (Quarterly)$2.81

P/S Ratio (Annual)33.68x

Asset Turnover (Annual)0.27x

52-Week High$212.75

Operating Margin (5Y Avg)-214.86%

EPS Excl Extra (Annual)$-6.42

CapEx CAGR (5Y)36.70%

Tangible BV CAGR (5Y)25.26%

26-Week Price Return-54.65%

Quick Ratio (Annual)3.35x

13-Week Price Return-34.37%

Total Debt / Equity (Annual)0.98x

Current Ratio (Quarterly)4.47x

Enterprise Value$20.57B

Revenue / Share Growth (5Y)12.59%

Asset Turnover (TTM)0.36x

Book Value / Share Growth (5Y)3.40%

Revenue / Employee (Annual)$364,400

Inventory Turnover (Annual)1.07x

Pretax Margin (Annual)-209.71%

Cash / Share (Annual)$6.67

3-Month Return Std Dev69.91%

Gross Margin (5Y Avg)77.75%

Net Income / Employee (TTM)$-711,400

ROE (Last FY)-172.78%

Net Interest Coverage (Annual)-49.10x

EPS Basic Excl Extra (Annual)$-6.42

Receivables Turnover (TTM)7.24x

Total Debt / Equity (Quarterly)1.03x

EPS Incl Extra (TTM)$-5.74

Receivables Turnover (Annual)6.29x

ROI (TTM)-72.28%

P/S Ratio (TTM)24.92x

Pretax Margin (5Y Avg)-226.38%

Revenue / Share (Annual)$3.05

Tangible BV / Share (Annual)$2.99

Price vs S&P 500 (52W)5.16%

Year-to-Date Return-45.86%

5-Day Price Return-11.14%

EPS Normalized (Annual)$-6.42

ROA (5Y Avg)-44.38%

Net Profit Margin (Annual)-210.54%

Month-to-Date Return-11.87%

Cash Flow / Share (TTM)$-5.17

EBITD / Share (Annual)$-6.23

Operating Margin (Annual)-205.59%

LT Debt / Equity (Annual)0.95x

ROI (5Y Avg)-54.58%

LT Debt / Equity (Quarterly)1.00x

EPS Basic Excl Extra (TTM)$-5.74

P/TBV (Quarterly)57.93x

P/B Ratio (Annual)50.23x

Inventory Turnover (TTM)1.28x

Pretax Margin (TTM)-143.76%

Book Value / Share (Annual)$3.45

Price vs S&P 500 (13W)-42.63%

Beta0.84x

Revenue / Share (TTM)$3.80

ROE (TTM)-130.11%

52-Week Low$70.57

vGradeF

gGradeA

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.76est. -0.98

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.26

4.27

4.31

4.29

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
INSMInsmed, Inc.	F	A	D	$94.22
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Insmed is a biopharmaceutical company with two commercial respiratory products, Arikayce and Brinsupri, which generate revenue primarily from the United States. Its clinical pipeline spans respiratory, immunology, inflammation, and rare neurological disorders, including programs TPIP, INS1148, brensocatib, and INS1201. Pre-clinical research encompasses gene therapy, AI-driven protein engineering, and RNA end-joining technologies.